Nanoparticle or conventional adjuvants: which one improves immune response against Brucellosis

سال انتشار: 1398
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 318

فایل این مقاله در 7 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_IJBMS-22-4_004

تاریخ نمایه سازی: 20 مهر 1398

چکیده مقاله:

Objective(s): Brucellosis is a common infectious disease among animals and humans. While subunit vaccines could be used as an efficient strategy against pathogens, they usually seem to be less immunogenic than live or killed vaccines. However, the use of a suitable adjuvant accompanied by subunit vaccines can be a good alternative to enhance the immune response.Materials and Methods: To find a proper adjuvant against Brucellosis, the immune response of induced mice by Aluminum Hydroxide (AH), Incomplete Freund (IFA), and Chitosan Nanoparticle (CS) adjuvants in individuals and in combination with CS were assessed.Results: Immunization with CS stimulated higher interferon gamma (IFN-γ) immunity, while there were no significant differences between rOMP25 (IFA), rOMP25 (AH), rOMP25 (AH-CS) and rOMP25 (IFA-CS) recombinant proteins. Tumor necrosis factor alpha (TNF-α) analysis revealed there were no significant differences between immunized groups and the positive control group, except for the treatment formulated in single IFA. Furthermore, unlike IFN-γ, there was a reverse interleukin-4 (IL-4) immune response trend for treatments, as rOMP25 (CS) displayed the lowest response. rOMP25 (CS) induced higher titer of total antibody than the other ones. Although the recombinant proteins emulsified in different adjuvants induced similar titer of IgG1 antibody, the ones that were formulated in CS, IFA and IFA-CS showed a higher titer of IgG2a. The cell proliferation assay demonstrating the antigen-specific cell proliferative response could be promoted after immunization with CS. Conclusion: CS whether single or in combination with IF adjuvants has potential to improve Th1-Th2 responses.

کلیدواژه ها:

نویسندگان

Soheil Yousefi

Department of Animal Science, Ferdowsi University of Mashhad, Mashhad, Iran

Tooba Abbassi-Daloii

Department of Animal Science, Ferdowsi University of Mashhad, Mashhad, Iran

Mojtaba Tahmoorespour

Department of Animal Science, Ferdowsi University of Mashhad, Mashhad, Iran

Mohammad Hadi Sekhavati

Department of Animal Science, Ferdowsi University of Mashhad, Mashhad, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Lee S, Nguyen MT. Recent advances of vaccine adjuvants for ...
  • Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future ...
  • Ramon G. Sur l’augmentation anormale de l’antitoxine chez les chevaux ...
  • Apostólico JdS, Lunardelli VAS, Coirada FC, Boscardin SB, Rosa DS. ...
  • Pasquale AD, Preiss S, Silva FTD, Garçon N. Vaccine adjuvants: ...
  • Carvalho TF, Haddad JPA, Paixão TA, Santos RL. Meta-Analysis and ...
  • Douce G, Turcotte C, Cropley I, Roberts M, Pizza M, ...
  • Marx PA, Compans RW, Gettie A, Staas JK, Gilley RM, ...
  • McElrath MJ. Selection of potent immunological adjuvants for vaccine construction. ...
  • Singh M, O’hagan DT. Recent advances in vaccine adjuvants. Pharm ...
  • Glenny A, Pope C, Waddington H, Wallace U. The antigenic ...
  • Vogel FR, Powell MF. A compendium of vaccine adjuvants and ...
  • Morefield GL, Sokolovska A, Jiang D, HogenEsch H, Robinson JP, ...
  • Brewer JM, Conacher M, Satoskar A, Bluethmann H, Alexander J. ...
  • Schirmbeck R, Melber K, Mertens T, Reimann J. Antibody and ...
  • Traquina P, Morandi M, Contorni M, Van Nest G. MF59 ...
  • Audibert FM, Lise LD. Adjuvants: current status, clinical perspectives and ...
  • Goto N, Kato H, Maeyama J, Eto K, Yoshihara S. ...
  • Freund J, Casals J, Hosmer EP. Sensitization and antibody formation ...
  • Stuart-Harris C. Adjuvant influenza vaccines. Bull World Health Organ 1969;41:615-621. ...
  • Lindblad EB. Aluminium compounds for use in vaccines. Immunol Cell ...
  • Freund J. The mode of action of immunologic adjuvants. Bibl ...
  • Moreira LO, Smith AM, DeFreitas AA, Qualls JE, El Kasmi ...
  • Knorr D. Use of chitinous polymers in food: a challenge ...
  • Kurita K. Chemistry and application of chitin and chitosan. Polym ...
  • dong Zhu B, qing Qie Y, ling Wang J, Zhang ...
  • Nishimura K, Nishimura S, Nishi N, Saiki I, Tokura S, ...
  • Peluso G, Petillo O, Ranieri M, Santin M, Ambrosic L, ...
  • Seferian PG, Martinez ML. Immune stimulating activity of two new ...
  • Shibata Y, Foster LA, Metzger WJ, Myrvik QN. Alveolar macrophage ...
  • Suzuki K, Okawa Y, Hashimoto K, Suzuki S, Suzuki M. ...
  • Van der Lubben I, Verhoef J, Borchard G, Junginger H. ...
  • Villiers C, Chevallet M, Diemer H, Couderc R, Freitas H, ...
  • De Campos AM, Sánchez A, Alonso MaJ. Chitosan nanoparticles: a ...
  • Yousefi S, Tahmoorespur M, Sekhavati MH. Cloning, expression and molecular ...
  • Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory ...
  • Ghasemi A, Jeddi-Tehrani M, Mautner J, Salari MH, Zarnani A-H. ...
  • Lambrecht BN, Kool M, Willart MA, Hammad H. Mechanism of ...
  • Marrack P, McKee AS, Munks MW. Towards an understanding of ...
  • GIES WJ. Some objections to the use of alum baking-powder. ...
  • Tomljenovic L, A Shaw C. Aluminum vaccine adjuvants: are they ...
  • Salk JE, Laurent AM. The use of adjuvants in studies ...
  • Savelkoul HF, Ferro VA, Strioga MM, Schijns VE. Choice and ...
  • Carroll EC, Jin L, Mori A, Muñoz-Wolf N, Oleszycka E, ...
  • Pasquali P, Adone R, Gasbarre LC, Pistoia C, Ciuchini F. ...
  • Jiang X, Baldwin CL. Effects of cytokines on intracellular growth ...
  • Araya LN, Elzer PH, Rowe GE, Enright FM, Winter AJ. ...
  • Zhan Y, Kelso A, Cheers C. Differential activation of Brucella-reactive ...
  • Scharf O, Agranovich I, Lee K, Eller NL, Levy L, ...
  • Wen Z-S, Xu Y-L, Zou X-T, Xu Z-R. Chitosan nanoparticles ...
  • Abbassi-Daloii T, Yousefi S, Sekhavati MH, Tahmoorespur M. Impact of ...
  • Yousefi S, Abbassi-Daloii T, Sekhavati MH, Tahmoorespur M. Evaluation of ...
  • Abkar M, Lotfi AS, Amani J, Eskandari K, Ramandi MF, ...
  • Abkar M, Fasihi-Ramandi M, Kooshki H, Sahebghadam Lotfi A. Oral ...
  • Amidi M, Romeijn SG, Verhoef JC, Junginger HE, Bungener L, ...
  • Vasiliev YM. Chitosan-based vaccine adjuvants: incomplete characterization complicates preclinical and ...
  • Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate ...
  • Mori A, Oleszycka E, Sharp FA, Coleman M, Ozasa Y, ...
  • Riteau N, Sher A. Chitosan: an adjuvant with an unanticipated ...
  • نمایش کامل مراجع